🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

200+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 200 recruiting trials for “large-granular-lymphocyte-leukemia

NARecruitingNCT05626400

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

🏥 Hebei Senlang Biotechnology Inc., Ltd.📍 1 site📅 Started Aug 2022View details ↗
Enrolling by InvitationNCT05509855

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

👨‍⚕️ Cherry Thomas, MD, Wugen, Inc.📍 5 sites📅 Started Aug 2022View details ↗
RecruitingNCT05334069

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

👨‍⚕️ Marie Wood, MD, University of Colorado, Denver📍 740 sites📅 Started Aug 2022View details ↗
Phase 3RecruitingNCT05254743

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

👨‍⚕️ Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company📍 144 sites📅 Started Jul 2022View details ↗
RecruitingNCT04785989

In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)

👨‍⚕️ Christopher Fletcher, MD, School of Medicine and Public Health, University of Wisconsin, Madison📍 1 site📅 Started Jun 2022View details ↗
RecruitingNCT05750706

Incidence of Invasive Fungal Infections Among Patients With Acute Lymphoblastic Leukemia Ph-negative

👨‍⚕️ Marianna Criscuolo, Fondazione Policlinico Universitario A. Gemelli, IRCCS📍 1 site📅 Started Jun 2022View details ↗
NARecruitingNCT06475469

Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk

🏥 CHU de Reims📍 1 site📅 Started May 2022View details ↗
Phase 1, PHASE2RecruitingNCT05294731

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

👨‍⚕️ Study Director, BeiGene📍 29 sites📅 Started May 2022View details ↗
Phase 3RecruitingNCT05197192

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

👨‍⚕️ Barbara Eichhorst, MD, Prof., Department I of Internal Medicine, University Hospital Cologne📍 30 sites📅 Started Apr 2022View details ↗
Phase 2RecruitingNCT05376111

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

🏥 The First Affiliated Hospital of Soochow University📍 1 site📅 Started Apr 2022View details ↗
Phase 2RecruitingNCT05648019

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

👨‍⚕️ Shui Yen Soh, MD, KK Women's and Children's Hospital📍 2 sites📅 Started Mar 2022View details ↗
Phase 2RecruitingNCT05082519

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

🏥 Etan Orgel📍 20 sites📅 Started Mar 2022View details ↗
RecruitingNCT05840575

Investigating Cognitive Impairment in Young Patients With Cancer Prospectively

🏥 Rigshospitalet, Denmark📍 1 site📅 Started Mar 2022View details ↗
NARecruitingNCT04929899

Bright Ideas - CIN Feasibility Study

👨‍⚕️ Lee Dupuis, PhD, SickKids Research Institute📍 4 sites📅 Started Mar 2022View details ↗
Phase 2RecruitingNCT05168930

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

👨‍⚕️ Inhye E Ahn, MD, Dana-Farber Cancer Institute📍 4 sites📅 Started Feb 2022View details ↗
Phase 1RecruitingNCT05210907

Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

🏥 Seoul National University Hospital📍 1 site📅 Started Feb 2022View details ↗
Phase 2RecruitingNCT05183854

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

👨‍⚕️ Daniel Ermann, MD, Huntsman Cancer Institute/ University of Utah📍 1 site📅 Started Jan 2022View details ↗
Phase 1, PHASE2RecruitingNCT05006716

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

👨‍⚕️ Study Director, BeOne Medicines📍 120 sites📅 Started Sep 2021View details ↗
Phase 1RecruitingNCT04704323

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

🏥 Catapult Therapeutics📍 4 sites📅 Started Sep 2021View details ↗
RecruitingNCT05014165

Backtracking Leukemia-Typical Somatic Mutations in Cord Blood

👨‍⚕️ Adam de Smith, PhD, University of Southern California Keck School of Medicine📍 1 site📅 Started Aug 2021View details ↗
← PreviousPage 8 of 10Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →